Hear the most up-to-date best practices, including shared decision-making, regarding treating patients with CLL in this post-COVID era.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Patients with Chronic Lymphocytic Leukemia (CLL) are considered highly susceptible to bacteria and viruses due to immunocompromisation. Now, in the post-COVID era, we are facing multiple viruses at the same time (i.e., Influenza, RSV, and COVID). It is as important as ever for patients with CLL to continue receiving vaccinations, as well as following safety and preventive measures such as wearing masks and social distancing. CANCER BUZZ spoke to Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, Co-Founder, Executive Vice President, and Chief Medical Officer at the CLL Society in Chula Vista, CA. Hear the most up-to-date best practices, including shared decision-making, regarding treating patients with CLL in this post-COVID era.
Guest


Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd
Co-Founder, Executive Vice President, and Chief Medical Officer
CLL Society
Chula Vista, CA
“The pandemic forced into the spotlight the reality that all CLL patients, regardless of their treatment status, even those who have not been treated, are immunocompromised. Patients had to make shifts in their lifestyle.
I think it is important that CLL patients realize that the pandemic is not over for the immunocompromised. And the virus that causes Covid infections, is not going away.”
– Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd
This project is supported by AbbVie.
Resources:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026

At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
